XML 31 R14.htm IDEA: XBRL DOCUMENT
v3.25.3

GOODWILL AND INTANGIBLE ASSETS | 12 Months Ended
--- | ---
Oct. 03, 2025
Goodwill and Intangible Assets Disclosure [Abstract] |
GOODWILL AND INTANGIBLE ASSETS | GOODWILL AND INTANGIBLE ASSETS The following table reflects goodwill by reportable operating segment:
(In millions) | Medical |  | Industrial |  | Total
Balance at September 27, 2024 | $ | 173.0 |  |  | $ | 118.0 |  |  | $ | 291.0 |
Impairment of goodwill | (93.9) |  |  | — |  |  | (93.9) |
Foreign currency translation adjustments | 0.7 |  |  | 0.6 |  |  | 1.3 |
Balance at October 3, 2025 | $ | 79.8 |  |  | $ | 118.6 |  |  | $ | 198.4 |
| Medical |  | Industrial |  | Total
Balance at October 3, 2025 |  |  |  |  |
Goodwill | $ | 173.7 |  |  | $ | 118.6 |  |  | $ | 292.3 |
Accumulated impairment losses | (93.9) |  |  | — |  |  | (93.9) |
Total goodwill | $ | 79.8 |  |  | $ | 118.6 |  |  | $ | 198.4 |
The Company performs its annual goodwill impairment test as of the beginning of the fourth quarter of each fiscal year or whenever an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Refer to Note 1, Summary of Significant Accounting Policies, for further details concerning our annual goodwill impairment evaluation. During the three months ended July 4, 2025, the Company identified triggering events in its Industrial and Medical reporting units due to a sustained decline in its market capitalization, a sustained decline in its stock price, and downward revisions in its longer-term forecast received during the quarter, which included the impact of tariffs and MOFCOM Investigations announcements. As a result, in connection with the preparation of its financial statements for the three months ended July 4, 2025, the Company performed a quantitative impairment analysis for goodwill related to its Medical and Industrial reporting units. The fair value of the reporting units were determined using both an income approach utilizing the discounted cash flow method and market approach utilizing the public company market multiple method. Based on this analysis, the Company determined that the carrying amount of the Medical reporting unit exceeded fair value, and recorded a goodwill impairment charge of $93.9 million to its Medical reporting unit within impairment of goodwill in the Consolidated Statements of Operations. Additionally, based on the output of the analysis, the Company determined that the fair value of the Industrial reporting unit exceeded its carrying amount. Accordingly, no impairment charge was recorded relating to its Industrial reporting unit. The goodwill within the Medical reporting unit remains susceptible to future impairment charges. Any significant adverse change in the Company's near- or long-term projections or macroeconomic conditions would result in future impairment charges for the Medical reporting unit. The following table reflects the gross carrying amount and accumulated amortization of the Company’s finite-lived intangible assets included in intangible assets, net in the Consolidated Balance Sheets:
| October 3, 2025 |  | September 27, 2024
(In millions) | Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount |  | Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount
Acquired existing technology | $ | 74.9 |  |  | $ | (65.5) |  |  | $ | 9.4 |  |  | $ | 73.8 |  |  | $ | (63.5) |  |  | $ | 10.3 |
Patents, licenses and other | 6.2 |  |  | (6.2) |  |  | — |  |  | 12.6 |  |  | (12.6) |  |  | — |
Customer contracts and supplier relationship | 52.3 |  |  | (47.7) |  |  | 4.6 |  |  | 52.8 |  |  | (47.0) |  |  | 5.8 |
Total intangible assets | $ | 133.4 |  |  | $ | (119.4) |  |  | $ | 14.0 |  |  | $ | 139.2 |  |  | $ | (123.1) |  |  | $ | 16.1 |
Amortization expense for intangible assets was $4.0 million, $9.9 million, and $13.7 million in fiscal years 2025, 2024, and 2023, respectively. As of October 3, 2025, the estimated future amortization expense of intangible assets with finite lives is as follows:
(In millions) |
Fiscal Years: |
2026 | $ | 4.1 |
2027 | 3.8 |
2028 | 3.7 |
2029 | 1.9 |
2030 | 0.2 |
Thereafter | 0.3 |
Total | $ | 14.0 |

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration